JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

The New York Giants better be careful they don't waste Malik Nabers' talent before he decides to follow Saquon Barkley's example. Washington Commanders v New York Giants / Luke Hales/GettyImages ...

Malik Monk tries to explain tonight’s 130-111 loss to the Magic, evaluates his performance, reacts to losing De’Aaron Fox, addition of Zach LaVine and Jonas Valanciunas, as well as the future ...

Zayn Malik bid farewell to his first-ever solo concert shows as his Stairway to the Sky tour, came to an end in UK and US earlier this week. The singer shared highlights on social media in a ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author.

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley boosted their FY2024 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, February 5th.

In related news, EVP Fady Ibraham Malik sold 2,000 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $48.06, for a total value ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten ...